Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis

By Tigran Makunts, Isaac V. Cohen, Linda Awdishu& Ruben Abagyan: For More Info, Go Here…

ngd-This is REALLY scary information…..

In this study of over ten million FDA Adverse Event Reporting System records, we provided evidence of kidney injury and electrolyte imbalances in an alarming number of patients taking PPIs. Additionally, we assessed differences between specific PPIs and observed significant electrolyte and renal abnormalities for each individual drug with varying magnitudes.

Conclusion

In our study we observed various levels of increased risk of renal and electrolyte ADRs in FAERS reports of individual PPI drugs with respect to H2RA reports. Regardless of which PPI is initiated, it may be beneficial to follow dosing and duration recommendations established by the FDA11,43,44,52,53,54, American College of Gastroenterology47,48 and World Gastroenterology Organisation Global Guidelines49. It may be beneficial to monitor renal function and electrolytes including potassium, calcium, magnesium, and sodium. Although H2RAs have not been shown to be as effective as PPIs, they might be considered as alternatives for patients who are at high risk for developing renal and electrolytes imbalances.

Leave a Reply